Literature DB >> 6221692

In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.

P E Varaldo, E Debbia, G C Schito.   

Abstract

The antibacterial activity of teichomycin, a glycopeptide antibiotic similar to vancomycin, has been evaluated in vitro and compared with that of vancomycin. Test strains included 130 staphylococci and 132 streptococci, with representatives of the major currently recognized species or groups, and lesser numbers of clostridia, propionibacteria, and group JK bacteria. Teichomycin was found to be more active than vancomycin. Its minimum inhibitory concentration (MIC) was two- to fourfold lower than that of vancomycin with staphylococci and anaerobic bacteria, and two- to eightfold lower with streptococci. No significant differences were observed with group JK bacteria. For most strains tested, minimum bactericidal concentrations (MBCs) of both teichomycin and vancomycin either equalled or exceeded by twofold the respective MICs. Higher MBC-to-MIC ratios were obtained for enterococci and pneumococci with both antibiotics. Both teichomycin and vancomycin showed similar in vitro interactions with rifampin in combination tests. Neither antagonism nor (with very few exceptions) synergism occurred.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221692      PMCID: PMC184660          DOI: 10.1128/AAC.23.3.402

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Characterization and identification of 95 diphtheroid (group JK) cultures isolated from clinical specimens.

Authors:  P S Riley; D G Hollis; G B Utter; R E Weaver; C N Baker
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

2.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

3.  Severe staphylococcal infections treated with vancomycin.

Authors:  M T Cafferkey; R Hone; C T Keane
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

4.  Simplified lyogroup system, a new method for routine identification of staphylococci: description and comparison with three other methods.

Authors:  P E Varaldo; G Grazi; O Soro; G Cisani; G Satta
Journal:  J Clin Microbiol       Date:  1980-07       Impact factor: 5.948

5.  Antibiotic-resistant group JK bacteria in hospitals.

Authors:  V J Gill; C Manning; M Lamson; P Woltering; P A Pizzo
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

7.  Nafcillin-tolerant Staphylococcus epidermidis endocarditis.

Authors:  J D Arthur; J W Bass; J F Keiser; L B Harden; S L Brown
Journal:  JAMA       Date:  1982 Jan 22-29       Impact factor: 56.272

8.  Colitis induced by Clostridium difficile.

Authors:  J G Bartlett; T Chang; N S Taylor; A B Onderdonk
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

9.  Vancomycin therapy of bacterial endocarditis.

Authors:  E W Hook; W D Johnson
Journal:  Am J Med       Date:  1978-09       Impact factor: 4.965

10.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.

Authors:  M R Keighley; D W Burdon; Y Arabi; J A Williams; H Thompson; D Youngs; M Johnson; S Bentley; R H George; G A Mogg
Journal:  Br Med J       Date:  1978-12-16
View more
  28 in total

1.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Pharmacokinetics of teicoplanin in hemodialysis patients.

Authors:  D Höffler; P Koeppe; E Naumann; E Lang; F Sörgel
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

3.  Thermodynamic analysis of the interaction of the antibiotic teicoplanin and its aglycone with cell-wall peptides.

Authors:  P Arriaga; J Laynez; M Menendez; J Cañada; F Garcia-Blanco
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

4.  Activity of teicoplanin against coagulase-negative staphylococci isolated from patients undergoing continuous peritoneal dialysis.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

5.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.

Authors:  E Debbia; A Pesce; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

7.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 8.  Current problems of chemotherapy of infections with coagulase-negative staphylococci.

Authors:  A J Davies; J W Stone
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

9.  Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.

Authors:  N Margreth van der Lugt; Sylke J Steggerda; Frans J Walther
Journal:  BMC Pediatr       Date:  2010-11-19       Impact factor: 2.125

10.  Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.

Authors:  C U Tuazon; H Miller
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.